Tadalafil: A long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension

Clinical Therapeutics

Volumn 33, Issue 8, 2011, Pages 993-1004

  Arif, Sally A ^a,b   Poon, Henry ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Phosphodiesterase 5 inhibitor; Pulmonary arterial hypertension; Tadalafil

Indexed keywords

PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

BACKACHE; BIBLIOGRAPHIC DATABASE; CLINICAL EVALUATION; DATA ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EVIDENCE BASED PRACTICE; EXERCISE; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTRITIS; HEADACHE; HISTIOCYTOSIS; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INFORMATION RETRIEVAL; KIDNEY ARTERY STENOSIS; MEDICAL RECORD; MEDLINE; MENORRHAGIA; MYALGIA; NAUSEA; PRIAPISM; PUBLISHING; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG INTERACTIONS; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PHOSPHODIESTERASE 5 INHIBITORS; VASODILATOR AGENTS;

EID: 80051609898     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.06.008     Document Type: Review

References (49)

1. Pietra G.G., Capron F., Stewart S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004, 43(Suppl 1):25-32.
2. Humbert M., Morrell N., Archer S., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(Suppl 1):13-24.
3. Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109:159-165.
4. Simonneau G., Galié N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43:5S-12S.
5. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119:2250-2294. [published correction appears in Circulation. 2009;120:e13].
6. Galié N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009, 30:2493-2537.
7. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
8. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111:3105-3111.
9. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
10. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161:487-492.
11. Eysmann S.B., Palevsky H.I., Reicheck N., et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989, 80:353-360.
12. Galié N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group, [published correction appears in N Engl J Med. 2006;354:2400-2401].
13. Sastry B.K., Narasimhan C., Reddy N.K., Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension, I: a randomized, placebo controlled, double-blind, crossover study. J Am Coll Cardiol 2004, 43:1149-1153.
14. Wilkens H., Guth A., Konig J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218-1222.
15. Singh T., Rohit M., Grover A., et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006, 151. 851e1-851e5.
16. Simonneau G., Rubin L., Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 2008, 149:521-530. Pulmonary Arterial Hypertension Combination Study of Epoprostenol and Sildenafil (PACES) Study Group.
17. Pepke-Zaba J., Gilbert C., Collings L., Brown M.C. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008, 133:183-189.
18. Adcirca (tadalafil) 2009, [package insert], Eli Lilly and Company, Indianapolis, Ind.
19. Tsai B.M., Turrentine M.W., Sheridan B.C., et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 2006, 81:272-278.
20. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:68S-72S.
21. Wharton J., Strange J.W., Moller G.M., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113.
22. Jeon Y.H., Heo Y.S., Kim C.M., et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 2005, 62:1198-1220.
23. Matot I., Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 2004, 125:644-651.
24. Rabe K.F., Tenor H., Dent G., et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol Lung Cell Mol Physiol 1994, 266:L536-L543.
25. Clinical Pharmacology and Biopharmaceutics Review(s). Center for Drug Evaluation and Research. US Food and Drug Administration. Tadalafil oral tablets, 20 mg, NDA 22-332 Accessed April 30, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022332s000_ClinPharmR.pdf.
26. Clinical Pharmacology and Biopharmaceutics Review(s). Center for Drug Evaluation and Research. US Food and Drug Administration. Tadalafil oral tablets, 5, 10, and 20 mg, NDA 21-368 Accessed April 30, 2010. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P1.pdf.
27. Daugan A., Grondin P., Ruault C., et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2:2,3,6,7,12,12a-hexahydropyrazinol[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues. J Med Chem 2003, 46:4533-4542.
28. Forgue S.T., Patterson B.E., Bedding A.W., et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2005, 61:280-288.
29. Gupta M., Kovar A., Meiboh B. Clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005, 45:987-1003.
30. Forgue S.T., Phillips D.L., Bedding A.W., et al. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol 2007, 63:24-35.
31. Tay E.L., Geok-Mui M.K., Poh-Hoon M.C., Yip J. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients. Int J Cardiol 2008, 125:416-417.
32. Ghofrani H.A., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. A randomized prospective study. J Am Coll Cardiol 2004, 44:1488-1496.
33. Mukhopadhyay S., Sharma M., Ramakrishnan S., et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a preliminary observational study. Circulation 2006, 114:1807-1810.
34. Galié N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
35. Macchia A., Marchioli R., Marfisi R., et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007, 153:1037-1047.
36. Oudiz R.J., Beardsworth A., Chan M.L., et al. Blinded, long-term safety and efficacy of tadalafil in treatment for pulmonary arterial hypertension. Am J Respir Crit Care Med 2009, 179:A1042.
37. Palmieri E.A., Lembo D. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004, 141:743-744.
38. Affuso F., Palmieri E.A., Di Conza P., et al. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension. Int J Cardiol 2006, 108:429-431.
39. de Carvalho A.C., Hovnanian A.L., Fernandes C.J., et al. Tadalafil as treatment for idiopathic pulmonary arterial hypertension. Arq Bras Cardiol 2006, 87:195-197.
40. Wrishko R.E., Dingemanse J., Yu A., et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008, 48:610-618.
41. Bendayan D., Shitrit D., Kramer M.R. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. Respirology 2008, 13:916-918.
42. Kloner R.A., Jackson G., Hutter A.M., et al. Cardiovascular safety update of tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006, 97:1778-1784.
43. Burgess G., Hoogkamer H., Collings L., Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008, 64:43-50.
44. Spence R., Mandagere A., Harrison B., et al. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. J Pharm Sci 2009, 98:4962-4974.
45. Kloner R.A., Hutter A.M., Emmick J.T., et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003, 42:1855-1860.
46. Kloner R.A., Jackson G., Emmick J.T., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004, 172:1935-1940.
47. Giuliano F., Kaplan S.A., Cabanis M.J., et al. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006, 67:1199-1204.
48. Ring B.J., Patterson B.E., Mitchell M.I., et al. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 2005, 77:63-75.
49. Drug prices and information Drugstore.com, Accessed August 20, 2010. http://www.drugstore.com/adcirca/20mg-tablets/qxn66302046760.